Voxilaprevir

Voxilaprevir
Clinical data
Trade names	Vosevi (combination with sofosbuvir and velpatasvir)
Identifiers
	IUPAC name (1R,18R,20R,24S,27S,28S)-N-[(1R,2R)-2-(Difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-28-ethyl-13,13-difluoro-7-methoxy-24-(2-methyl-2-propanyl)-22,25-dioxo-2,21-dioxa-4,11,23,26-tetraazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3(12),4,6,8,10-pentaene-27-carboxamide;
CAS Number	1535212-07-7;
PubChem CID	89921642;
ChemSpider	44209500;
UNII	0570F37359;
KEGG	D10899;
PDB ligand	L9P (PDBe, RCSB PDB);
Chemical and physical data
Formula	C40H52F4N6O9S
Molar mass	868.94 g·mol−1
3D model (JSmol)	;
Density	1.4±0.1 g/cm3
	SMILES CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]3(C[C@H]3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)[C@@H](NC(=O)O[C@@H]5C[C@H]5CCCCC(c6c(nc7cc(ccc7n6)OC)O2)(F)F)C(C)(C)C;
	InChI InChI=1S/C40H52F4N6O9S/c1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29/h11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53)/t20-,22-,23+,26-,27+,28+,30-,39-/m1/s1; Key:MZBLZLWXUBZHSL-FZNJKFJKSA-N;

Voxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor (by Gilead) that is used in combination with sofosbuvir and velpatasvir.^[2] The combination has the trade name Vosevi and received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017.^[3]

On 18 July 2017, Vosevi was approved by the US Food and Drug Administration.^[4]

References[edit]

^ "voxilaprevir_msds".
^ Heo YA, Deeks ED (April 2018). "Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C". Drugs. 78 (5): 577–587. doi:10.1007/s40265-018-0895-5. PMID 29546556. S2CID 4395880.
^ "Summary of opinion: Vosevi" (PDF). European Medicines Agency. 22 June 2017.
^ FDA approves Vosevi for Hepatitis C

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.